The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Approving low dose CT scanning to reduce lung cancer mortality
Frank McCaughan, MRCP(UK), MD, PhD, FRCP, University of Cambridge, Cambridge, UK, comments on the role of low dose computed tomography (CT) scans in early diagnosis of lung cancer. Data from multiple trials including the SUMMIT trial (NCT03934866) and Yorkshire Lung Screening Trial (NCT03750110) have demonstrated the efficacy of low dose CT scans in reducing lung cancer mortality. Despite the findings, low dose CT scanning has yet to be approved for nationwide usage in the UK and Dr McCaughan emphasizes the need to approve CT low dose CT scanning. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
